| Market Capitalization (Millions $) |
284 |
| Shares
Outstanding (Millions) |
80 |
| Employees |
86 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-13 |
| Cash Flow (TTM) (Millions $) |
17 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Sab Biotherapeutics Inc. is a biotechnology company that specializes in the development of human antibody therapeutics. They are known for their innovative platform technology, named the DiversitAb™ platform, which leverages genetically engineered cattle to produce fully human antibodies.
Using their platform, Sab Biotherapeutics aims to address various diseases and medical conditions, including cancer, infectious diseases, and autoimmune disorders. Their technology enables the production of large quantities of human antibodies in a relatively short period, allowing for more efficient drug development and potentially faster access to life-saving treatments.
The company's approach involves immunizing the genetically engineered cattle with specific antigens, which triggers the production of human antibodies. These antibodies are then harvested and purified for use in therapeutic applications. This unique technology offers several advantages, including improved safety, cost-effectiveness, and increased scalability compared to traditional methods of antibody production.
Sab Biotherapeutics has gained recognition for its work during the COVID-19 pandemic. They have been working on developing a potential treatment for the virus using their DiversitAb™ platform. Their product, called SAB-185, is an investigational antibody therapeutic that has shown promising results in preclinical studies. The company is actively collaborating with various partners and regulatory agencies to advance the development and potential approval of this therapy.
In summary, Sab Biotherapeutics Inc. is a biotech company that uses genetically engineered cattle to produce fully human therapeutic antibodies. Their innovative platform technology has the potential to revolutionize the field of antibody development and provide new treatment options for various diseases.
Company Address: 777 W 41st St Miami Beach 33140 FL
Company Phone Number: 679-6980 Stock Exchange / Ticker: NASDAQ SABS
|
0.01%